Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | CNR1 | P21554 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.58 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | FAAH | O00519 | 3/20 | 0.58 |
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4096417 | 1.00 | EPHX2 (0.60) | EPHX2MEN1KMT2ACNR1ALDH1A1 | |
| SCHEMBL4320018 | 1.00 | EPHX2 (0.60) | EPHX2MEN1KMT2ACNR1ALDH1A1 | |
| SCHEMBL2701073 | 1.00 | EPHX2 (0.60) | EPHX2MEN1KMT2ACNR1ALDH1A1 | |
| SCHEMBL2701074 | 1.00 | EPHX2 (0.60) | EPHX2MEN1KMT2ACNR1ALDH1A1 | |
| SCHEMBL2952168 | 0.96 | MEN1 (0.68) | MEN1KMT2ACNR1ALDH1A1HPGD | |
| SCHEMBL5029203 | 0.94 | EPHX2 (0.50) | EPHX2MEN1KMT2ACNR1ALDH1A1 | |
| SCHEMBL5028879 | 0.91 | EPHX2 (0.52) | EPHX2MEN1KMT2ACNR1ALDH1A1 | |
| SCHEMBL23521368 | 0.90 | FAAH (0.62) | MEN1KMT2AMAPTFAAH | |
| SCHEMBL1498601 | 0.90 | FAAH (0.62) | MEN1KMT2AMAPTFAAH | |
| SCHEMBL11513011 | 0.90 | FAAH (0.62) | MEN1KMT2AMAPTFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423066-B2 | Dietetics; use in treatment of obesity, for reducing body weight, modulating body lipid metabolism, and reducing food intake | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-09 | — | — | US | claimed |
| US-20050187254-A1 | Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-08-25 | — | — | US | claimed |
| US-6911474-B2 | Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-06-28 | — | — | US | claimed |
| US-7423066-B2 | Dietetics; use in treatment of obesity, for reducing body weight, modulating body lipid metabolism, and reducing food intake | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-09 | — | — | US | disclosed |
| US-20080103209-A1 | Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-05-01 | — | — | US | disclosed |
| US-20050187254-A1 | Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-08-25 | — | — | US | disclosed |
| US-20050154064-A1 | Dietary and other compositions, compounds, and methods for reducing body fat, controlling appetite, and modulating fatty acid metabolism | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-07-14 | — | — | US | disclosed |
| US-6911474-B2 | Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-06-28 | — | — | US | disclosed |
| US-20050101542-A1 | Combination therapy for controlling appetites | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2005-05-12 | — | — | US | disclosed |
| US-20050054730-A1 | Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-03-10 | — | — | US | disclosed |
| US-20030018081-A1 | Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101542-A1 | Combination therapy for controlling appetites | FAAH, FAAH2, GPR119 | EPHX2 330/4885MEN1 3474/4885KMT2A 1221/4885 |
| US-20080103209-A1 | Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists | FAAH, CNR2, FAAH2 | EPHX2 381/4885MEN1 4878/4885KMT2A 2333/4885 |
| US-20030018081-A1 | Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism | LIPC, FABP4, FASN | EPHX2 474/4885MEN1 2947/4885KMT2A 1456/4885 |
| US-20050187254-A1 | Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism | LIPC, FABP4, FASN | EPHX2 474/4885MEN1 2947/4885KMT2A 1456/4885 |
| US-20050054730-A1 | Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha | PPARA, CNR2, CNR1 | EPHX2 249/4885MEN1 4862/4885KMT2A 796/4885 |
| US-20050154064-A1 | Dietary and other compositions, compounds, and methods for reducing body fat, controlling appetite, and modulating fatty acid metabolism | FABP4, LIPC, FAAH | EPHX2 1366/4885MEN1 1821/4885KMT2A 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.